ES2194998T3 - Composiciones y formulaciones para producir analgesia y para inhibir la progresion de trastornos de dolor neuropatico. - Google Patents

Composiciones y formulaciones para producir analgesia y para inhibir la progresion de trastornos de dolor neuropatico.

Info

Publication number
ES2194998T3
ES2194998T3 ES96923511T ES96923511T ES2194998T3 ES 2194998 T3 ES2194998 T3 ES 2194998T3 ES 96923511 T ES96923511 T ES 96923511T ES 96923511 T ES96923511 T ES 96923511T ES 2194998 T3 ES2194998 T3 ES 2194998T3
Authority
ES
Spain
Prior art keywords
progression
neuropathic pain
formulations
inhibit
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96923511T
Other languages
English (en)
Spanish (es)
Inventor
Gary Arthur Amstutz
Stephen Scott Bowersox
Kishorchandra Gohil
Peter Isadore Adriaenssens
Ramasharma Kristipati
Theresa Gadbois
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Elan Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/496,847 external-priority patent/US5795864A/en
Priority claimed from US08/613,400 external-priority patent/US6054429A/en
Application filed by Elan Pharmaceuticals LLC filed Critical Elan Pharmaceuticals LLC
Application granted granted Critical
Publication of ES2194998T3 publication Critical patent/ES2194998T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Control Of El Displays (AREA)
  • Saccharide Compounds (AREA)
ES96923511T 1995-06-27 1996-06-26 Composiciones y formulaciones para producir analgesia y para inhibir la progresion de trastornos de dolor neuropatico. Expired - Lifetime ES2194998T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/496,847 US5795864A (en) 1995-06-27 1995-06-27 Stable omega conopetide formulations
US08/613,400 US6054429A (en) 1996-03-08 1996-03-08 Epidural method of producing analgesia

Publications (1)

Publication Number Publication Date
ES2194998T3 true ES2194998T3 (es) 2003-12-01

Family

ID=27052304

Family Applications (2)

Application Number Title Priority Date Filing Date
ES96923511T Expired - Lifetime ES2194998T3 (es) 1995-06-27 1996-06-26 Composiciones y formulaciones para producir analgesia y para inhibir la progresion de trastornos de dolor neuropatico.
ES03007342T Expired - Lifetime ES2283671T3 (es) 1995-06-27 1996-06-26 Composiciones y formulaciones para producir analgesia y para inhibir la progresion de transtornos de dolor neuropatico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES03007342T Expired - Lifetime ES2283671T3 (es) 1995-06-27 1996-06-26 Composiciones y formulaciones para producir analgesia y para inhibir la progresion de transtornos de dolor neuropatico.

Country Status (13)

Country Link
EP (2) EP1336409B1 (enExample)
JP (1) JP2838073B2 (enExample)
AT (2) ATE359086T1 (enExample)
AU (1) AU695166B2 (enExample)
CA (1) CA2224795C (enExample)
DE (3) DE69637021T2 (enExample)
DK (2) DK0835126T3 (enExample)
ES (2) ES2194998T3 (enExample)
FR (1) FR05C0027I2 (enExample)
LU (1) LU91181I2 (enExample)
NL (1) NL300201I2 (enExample)
PT (2) PT1336409E (enExample)
WO (1) WO1997001351A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5931809A (en) * 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
CA2319038A1 (en) * 1998-02-20 1999-08-26 Zeneca Limited Analgesic peptides from venom of grammostola spatulata and use thereof
AUPP627498A0 (en) 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
EP2412719A1 (en) 2002-12-02 2012-02-01 Xenome Ltd Chi-conotoxin peptides
WO2004050690A1 (en) 2002-12-02 2004-06-17 Xenome Ltd NOVEL χ-CONOTOXIN PEPTIDES (-I)
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1911763B1 (en) 2003-01-28 2010-08-11 Ironwood Pharmaceuticals, Inc. Compositions for the treatment of gastrointestinal disorders
CA2540895C (en) 2003-10-02 2016-08-02 Elan Pharmaceuticals, Inc. Combinations of ziconotide and opioids for reducing pain
GB0410215D0 (en) * 2004-05-07 2004-06-09 Lescroart Pol Nerve damage
US8188048B2 (en) 2006-06-23 2012-05-29 Xenome Limited Combination therapy
JP2010509209A (ja) * 2006-11-04 2010-03-25 エニジェン カンパニー リミテッド 新規なω−コノトキシン
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2300044A4 (en) * 2008-05-06 2012-04-18 Relevare Aust Pty Ltd METHOD AND COMPOSITIONS FOR TREATING PAIN WITH OMEGA CONOTOXINES
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US20100221329A1 (en) 2008-12-03 2010-09-02 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
MX381407B (es) 2008-12-31 2025-03-12 Ardelyx Inc Compuestos y métodos para inhibir el antiporte mediado por intercambiador de iones de sodio/iones de hidrógeno (nhe) en el tratamiento de trastornos asociados con retención de fluido o sobrecarga de sal y trastornos del tracto gastrointestinal.
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX366293B (es) 2012-08-21 2019-07-04 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
HRP20191000T1 (hr) 2013-04-12 2019-09-20 Ardelyx, Inc. Spojevi za vezanje nhe3 i metode inhibiranja transporta fosfata
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
MX2019008171A (es) 2017-01-09 2020-02-05 Ardelyx Inc Inhibidores del antiporte mediado por nhe.
MX395405B (es) 2017-01-09 2025-03-25 Ardelyx Inc Compuestos útiles para tratar trastornos del tracto gastrointestinal.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3926287A1 (de) * 1989-08-09 1991-02-21 Bernhard Clasbrummel Medizinische anwendung von omega-conotoxin gvia oder omega-conotoxin gvia-analoga zur sympathikolyse
US5051403A (en) * 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
AU3074592A (en) * 1991-11-12 1993-06-15 Neurex Corporation Compositions for delayed treatment of ischemia-related neuronal damage
WO1993013128A1 (en) * 1991-12-30 1993-07-08 Neurex Corporation Methods of producing analgesia and enhancing opiate analgesia
JPH06247879A (ja) * 1993-02-17 1994-09-06 Bristol Myers Squibb Co デオキシチミジンヌクレオシドを含有する注射用製剤の安定化方法およびその方法によって得られる安定化注射用製剤

Also Published As

Publication number Publication date
CA2224795A1 (en) 1997-01-16
WO1997001351A1 (en) 1997-01-16
AU695166B2 (en) 1998-08-06
FR05C0027I2 (enExample) 2006-12-29
PT835126E (pt) 2003-07-31
DK0835126T3 (da) 2003-07-14
EP0835126B1 (en) 2003-04-02
FR05C0027I1 (enExample) 2005-08-12
JP2838073B2 (ja) 1998-12-16
AU6400296A (en) 1997-01-30
NL300201I1 (nl) 2005-09-01
EP0835126A1 (en) 1998-04-15
HK1058146A1 (en) 2004-05-07
DE69637021D1 (de) 2007-05-24
NL300201I2 (nl) 2006-02-01
ATE235914T1 (de) 2003-04-15
LU91181I2 (fr) 2005-09-06
DE122005000043I2 (de) 2006-08-03
EP1336409B1 (en) 2007-04-11
CA2224795C (en) 2001-04-03
DE69627153T2 (de) 2003-12-04
DE69627153D1 (de) 2003-05-08
JPH09104634A (ja) 1997-04-22
ES2283671T3 (es) 2007-11-01
DK1336409T3 (da) 2007-08-13
EP1336409A1 (en) 2003-08-20
DE69637021T2 (de) 2008-01-10
ATE359086T1 (de) 2007-05-15
DE122005000043I1 (de) 2006-06-29
PT1336409E (pt) 2007-06-29

Similar Documents

Publication Publication Date Title
ES2194998T3 (es) Composiciones y formulaciones para producir analgesia y para inhibir la progresion de trastornos de dolor neuropatico.
UY24005A1 (es) Dentrifico antiseptico
ITMI951278A0 (it) Formulazioni di analoghi dell'insulina
TR199600498A2 (tr) S(+)-ibuprofen'in oral formülasyonlari.
CA2222676A1 (en) New pharmaceutical composition with anaesthetic effect
MY115662A (en) Novel compounds with analgesic effect
BR9712491A (pt) Composições cosméticas
CA2219502A1 (en) Methods and formulations for modulating the human sexual response
MX9207317A (es) Composiciones desensibilizadoras de la dentina.
FR2757370B1 (fr) Plaque perfectionnee d'osteosynthese femorale
TR199600499A2 (tr) S(+)-Etodolak'in oral formülasyonlari.
FI953915A0 (fi) Dupuytrenin taudin lievittämiseen
BR9808302A (pt) O uso de levobupivacaìna na cirurgia pediátrica
EP0631772A3 (en) Agent containing retinoid.
EP0793478A4 (en) MEDIUM FOR THE MOUTH
HU9800623D0 (en) Oral application of "(+)-o-demethyl-tramadol as analgesic active component
AU3992897A (en) Use of sulbutiamine to obtain pharmaceutical compositions useful in the treatment of certain psychomotor and psycho-intellectual disorders
KR970000226A (ko) S-이부프로펜의 경구용 제형
FR2746315B1 (fr) Melange therapeutique pour massages a base d'huiles essentielles
FR2781369B1 (fr) Compositions cosmetiques antisolaires a base d'un melange synergique de filtres et utilisations
AU124671S (en) Elongate frame extension
ITAR910009U1 (it) Manipolo per sollecitazioni elettrostatiche dell'epidermide
TH6799S1 (th) เก้าอี้
ITBO960501A0 (it) Caramella all'aceto balsamico
TH11873S1 (th) แปรงสีฟัน